My Companies
Notification
Account
Log Out
Login
Shilpa Biologicals commissioned one of India's few integrated Antibody-Drug Conjugate GMP manufacturing facilities, designed to meet US FDA and EMA standards, positioning Shilpa Medicare as a cost-competitive CDMO partner for global oncology ADC drug substance manufacturing.
Shilpa Medicare Secures SEC Approval For First Extended-Release Ondansetron Injection
Shilpa Medicare Subsidiary FTF Pharma Enters Insolvency Resolution Process
Shilpa Medicare Inks Nivolumab Biosimilar Co-Development Deal with Finland's Orion